Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist
Choose a source to read (3)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
2 additional source qualifications - review before use
The official ER source has a once-daily dialysis starting regimen. Its maximum does not make IR and ER starting doses or indications interchangeable.
Before applying: Confirm exact release formulation and indication. The failed REQUIP XL mirror has not been recovered by adding an official generic label.
Severe renal impairment without regular dialysis was not studied. Verify XL and Parkinson disease indication.
Before applying: Verify the current prescribing information for this presentation.
Also check: ER Parkinson regimen is not the IR RLS schedule; Requip XL - product and source limitations
Official source
Requip XL - labeled renal guidance
Renal action and limits
Ropinirole (Requip XL), adult extended-release tablets for Parkinson disease Creatinine clearance (CrCl), mL/min; use the product-specific calculation
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Action or finding
At CrCl 30-50 mL/min there is no renal adjustment. With ESRD on regular HD, start at 2 mg once daily and limit the total to 18 mg/day. A post-HD supplement is unnecessary.
Limits and monitoring
Severe renal impairment without regular dialysis was not studied. Verify XL and Parkinson disease indication.
Before use
Verify the current prescribing information for this presentation.
Ropinirole (Requip XL), adult extended-release tablets for Parkinson disease
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
Prescribing information revised 3/2017
Retrieved
2026-11-07 (not the revision date)
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Renal guidance: 2, renal impairment
At CrCl 30-50 mL/min there is no renal adjustment. With ESRD on regular HD, start at 2 mg once daily and limit the total to 18 mg/day. A post-HD supplement is unnecessary. Severe renal impairment without regular dialysis was not studied. Verify XL and Parkinson disease indication.
Source revision: Prescribing information revised 3/2017 | Retrieved: 2026-11-07. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-specific interpretation
What the dialysis evidence actually supports
Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.
Requip XL - labeled renal guidance
Source retrieved 2026-11-07 - confirm current applicability
These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
scope and safety
ER Parkinson regimen is not the IR RLS schedule
The official ER source has a once-daily dialysis starting regimen. Its maximum does not make IR and ER starting doses or indications interchangeable.
How to use this: Confirm exact release formulation and indication. The failed REQUIP XL mirror has not been recovered by adding an official generic label.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Official source
Ropinirole - extended-release tablets
Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.
Method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / Elite Laboratories, Inc. · Ropinirole - extended-release tablets; selected renal passages, not a complete prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Source date: Prescribing information revised November 2025. Retrieved: 2026-09-09
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
For Parkinson disease, CrCl 30-50 mL/min needs no adjustment. With regular hemodialysis, start extended-release ropinirole at 2 mg once daily and titrate to response and tolerability; maximum 18 mg/day. No supplemental postdialysis dose is required. Severe impairment below 30 without regular dialysis has not been studied. These once-daily tablets are not the immediate-release RLS regimen. Do not transfer the IR starting frequency or treat an ER tablet as interchangeable without the label-specific conversion instructions.
RDM52-official-ropinirole-extended-release-19b82add10-C1 · Source locator: Dosage and Administration: general dosing and renal impairment; Indications and Usage.
Source-specific limits
The RX REQUIP XL destination failed retrieval in this R pass. This official supplement is not counted as recovered RX content.
At CrCl 30-50 mL/min there is no renal adjustment. With ESRD on regular HD, start at 2 mg once daily and limit the total to 18 mg/day. A post-HD supplement is unnecessary. Severe renal impairment without regular dialysis was not studied. Verify XL and Parkinson disease indication.
GlobalRPh RX List / product-label mirror · Ropinirole (Requip XL), adult extended-release tablets for Parkinson disease
Renal method: Use the renal measure explicitly present in the RX passage. Source date: Mirror revision not established in the reviewed passage. Retrieved: 2026-11-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.
